EVE Partners with hubMed to Support Thousands with Dysmenorrhoea and Erectile Dysfunction
EVE Health Group has partnered with telehealth provider hubMed to deliver a national patient support program, enhancing care continuity for users of its Dyspro and Libbo therapies.
- EVE signs Patient Support Telehealth Services Agreement with hubMed
- Program targets women’s and men’s health conditions, dysmenorrhoea and erectile dysfunction
- Registered Nurses provide ongoing telehealth consultations to reinforce treatment adherence
- Partnership complements launches of Dyspro and upcoming Libbo products
- Expansion of digital support platforms including Reclaim My Cycle community
Strategic Partnership to Enhance Patient Care
EVE Health Group (ASX, EVE) has taken a significant step in expanding its patient support ecosystem by entering into a nationwide Telehealth Services Agreement with hubMed, a leading Australian telehealth provider. This collaboration aims to provide structured, accessible follow-up care for patients prescribed EVE’s innovative therapeutic products Dyspro and Libbo, addressing key unmet needs in women’s and men’s health.
The program is designed to improve continuity of care, a critical factor in managing conditions like dysmenorrhoea and erectile dysfunction, which often suffer from under diagnosis and inconsistent follow-up. Through regular telehealth consultations delivered by experienced Registered Nurses, patients will receive guidance on safe product use, symptom management, and timely escalation to their treating practitioners when necessary.
Addressing Significant Health Burdens
Dysmenorrhoea affects a majority of women of reproductive age, with substantial impacts on daily life and economic productivity. EVE’s Dyspro, a cannabinoid-based fast-acting pastille, targets this widespread condition and related endometriosis symptoms. Meanwhile, Libbo, an oral dissolving film for erectile dysfunction, offers a modern, convenient dosage form designed to improve adherence and patient acceptance in a condition often hindered by stigma and delayed treatment.
By integrating hubMed’s telehealth services, EVE aims to reinforce patient confidence and adherence, ensuring that users of Dyspro and Libbo receive ongoing clinical support beyond the initial prescription. This approach not only supports better real-world outcomes but also complements traditional healthcare pathways.
Expanding the Digital Support Ecosystem
Building on the launch of Dyspro, EVE recently introduced Reclaim My Cycle, an online community platform providing education and support for women managing dysmenorrhoea and endometriosis. The upcoming launch of Libbo will be accompanied by additional digital platforms focused on men’s health, creating a comprehensive ecosystem of evidence-based resources and patient engagement tools.
CEO Damian Wood highlighted the importance of this partnership, noting that reliable follow-up and trusted clinical support are vital for patients often overlooked in these therapeutic areas. hubMed’s Managing Director Jessica Stewart echoed this sentiment, emphasizing the value of continuity of care and patient wellbeing throughout treatment journeys.
As telehealth continues to reshape healthcare delivery, EVE’s integration of these services positions the company to better meet patient needs and potentially accelerate adoption of its novel therapies in large, underserved markets.
Bottom Line?
EVE’s telehealth partnership marks a pivotal move to deepen patient engagement and support, setting the stage for broader adoption of its women’s and men’s health therapies.
Questions in the middle?
- How will the telehealth program impact patient adherence and clinical outcomes over time?
- What financial benefits or cost efficiencies might EVE realize from this partnership?
- Will EVE expand telehealth support to additional therapeutic areas or markets?
